SCHEMBL6487707

SCHEMBL6487707

CCOc1ccc(-c2ccc(F)cc2)c(C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.57
PTPN11 Q06124 4/20 0.57
CHRNA7 P36544 2/20 0.52
FFAR4 Q5NUL3 2/20 0.51
FFAR1 O14842 1/20 0.51
HCRTR1 O43613 1/20 0.49
HCRTR2 O43614 1/20 0.49
PRKAB2 O43741 1/20 0.48
PRKAG1 P54619 1/20 0.48
PRKAA2 P54646 1/20 0.48
PRKAA1 Q13131 1/20 0.48
PRKAG3 Q9UGI9 1/20 0.48
PRKAG2 Q9UGJ0 1/20 0.48
PRKAB1 Q9Y478 1/20 0.48
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491926 0.87 SMN1; SMN2 (0.59) SMN1; SMN2PTPN11FFAR4FFAR1HCRTR1
SCHEMBL6640302 0.87 PTPN11 (0.59) SMN1; SMN2PTPN11HCRTR1HCRTR2KDM4E
SCHEMBL6492999 0.86 SMN1; SMN2 (0.57) SMN1; SMN2PTPN11CHRNA7FFAR4FFAR1
SCHEMBL6501365 0.85 PTPN11 (0.54) SMN1; SMN2PTPN11FFAR4FFAR1HCRTR1
SCHEMBL6490238 0.84 SMN1; SMN2 (0.82) SMN1; SMN2PTPN11PRKAB2PRKAG1PRKAA2
SCHEMBL6499746 0.81 ALDH1A1 (0.59) SMN1; SMN2PTPN11FFAR4KDM4EALDH1A1
SCHEMBL18311270 0.79 KAT6A (0.56) SMN1; SMN2FFAR4FFAR1KDM4EALDH1A1
SCHEMBL20275274 0.79 FFAR4 (0.48) CHRNA7FFAR4FFAR1KDM4ELMNA
SCHEMBL6498591 0.78 HSD17B10 (0.58) SMN1; SMN2KDM4ELMNAALDH1A1HPGD
SCHEMBL31586500 0.78 HSD17B10 (0.58) SMN1; SMN2KDM4ELMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SMN1; SMN2 1921/4885PTPN11 1450/4885CHRNA7 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.